文摘
摘要目的:评估123 i-fp-cit SPECT发现孤立的REM睡眠行为障碍(iRBD)改变纵向和异常是否123 i-fp-cit SPECT扫描之前,预测未来的过渡到一个公开的synucleinopathy。
背景:iRBD病人高危,开发一个公开synucleinopathy——特别是与路易体痴呆(下文)和帕金森病(PD)。减少黑吸收123 i-fp-cit SPECT反映出多巴胺不足。
设计/方法:从梅奥诊所参与者polysomnography-confirmed iRBD阿尔茨海默病研究中心数据库±北美前驱的Synucleinopathy(午睡)财团有两个或两个以上的纵向123 i-fp-cit SPECT扫描和前瞻性> 24个月包括(n = 34)。Striatonigral多巴胺转运体吸收是评估方法与123年i-fp-cit SPECT使用DaTQUANT 2.0软件(通用电气医疗集团)来计算壳核吸收的z得分。
结果:16个参与者(47%)开发了一个公开的synucleinopathy (phenoconverters)和18名参与者(53%)仍然iRBD iRBD(稳定)。后续年phenoconverters稳定iRBD没有差异(5.4±2.3 vs 5.7±1.8年)。在基线,phenoconverters年龄(69.1±6.1 vs 63.2±6.3岁),有更多的消极DaTQUANT壳z得分(−2.10±1.57 vs−0.26±1.19),后来开始RBD (62.3±8.1 vs 46.3±15.4岁),和短时间RBD (6.9±4.2 vs 16.9±12.4岁)比iRBD稳定。核z分数下降更快phenoconverters比稳定iRBD (z分数斜率−0.27±0.29 vs−0.05±0.23)。phenoconverters中,11个参与者(69%)有一个或多个核的z得分<−2.0 phenoconversion之前,时间从最初的核的z分数<−2.0 phenoconversion是3.1±2.2年。
结论:这些发现表明,iRBD下降患者硬膜吸收123 i-fp-cit SPECT,后来开始/短时间iRBD RBD与进程相关联的一个明显的synucleinopathy。
披露:Miyagawa博士没有披露。斯科特Przybelskihas nothing to disclose.Daniela Maltais has nothing to disclose.Hoon-Ki Min has nothing to disclose.Lennon Jordan has nothing to disclose.Timothy Lesnick has received personal compensation for serving as an employee of Mayo Clinic. Dr. Silber has received publishing royalties from a publication relating to health care. Dr. Silber has received personal compensation in the range of $500-$4,999 for serving as a Topic writer with UpToDate. Dr. McCarter has received personal compensation in the range of $0-$499 for serving as a Contributor with Medlink Neurology. Dr. St. Louis has received publishing royalties from a publication relating to health care. Dr. St. Louis has received publishing royalties from a publication relating to health care. Dr. Graff-Radford has received personal compensation for serving as an employee of Mayo Clinic. Dr. Graff-Radford has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Academy of Neurology. The institution of Dr. Graff-Radford has received research support from NIH. Dr. Jones has nothing to disclose. The institution of Dr. Savica has received research support from ACADIA Pharmaceuticals, Inc. Dr. Knopman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DIAN TU study. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche, Inc.. Dr. Petersen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen, Inc.. Dr. Petersen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eisai, Inc.. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck, Inc.. Dr. Petersen has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech, Inc.. Dr. Petersen has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche, Inc.. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. The institution of Walter Kremers has received research support from Biogen. Ms. Forsberg has nothing to disclose. The institution of Dr. Fields has received research support from National Institutes of Health. The institution of Dr. Fields has received research support from Patient-Centered Outcomes Research Institute. Ms. Ferman has nothing to disclose. Dr. Botha has nothing to disclose. Dr. Ramanan has nothing to disclose. Ms. Allen has nothing to disclose. The institution of Dr. Kantarci has received research support from Eli Lilly. The institution of Dr. Kantarci has received research support from NIH. The institution of Dr. Kantarci has received research support from ADDF. Dr. Lowe has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AVID Radiopharmaceutical. Dr. Lowe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Inc. The institution of Dr. Lowe has received research support from AVID Radiopharmaceuticals. Dr. Boeve has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Rainwater Charitable Foundation. The institution of Dr. Boeve has received research support from Biogen. The institution of Dr. Boeve has received research support from EIP Pharma. The institution of Dr. Boeve has received research support from Alector. The institution of Dr. Boeve has received research support from GE Healthcare. Dr. Boeve has received publishing royalties from a publication relating to health care.
